Recent News

• 12.10.2025 - ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk
• 12.01.2025 - ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
• 12.01.2025 - ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference
• 11.24.2025 - ProMIS Neurosciences Announces Reverse Stock Split
• 11.12.2025 - ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights
• 11.03.2025 - ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Recent Filings

• 11.24.2025 - EX-99.1 EX-99.1
• 11.24.2025 - 8-K Current report
• 11.19.2025 - 8-K Current report
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.12.2025 - 8-K Current report
• 11.12.2025 - EX-99.1 EX-99.1
• 11.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.29.2025 - SCHEDULE 13D General Statement of Acquisition of Beneficial Ownership
• 10.24.2025 - 4 Statement of changes in beneficial ownership of securities